The Science Behind CA-62
The CA-62 biomarker represents a breakthrough in early cancer detection science. Validated in over 5,000 clinical samples and published in peer-reviewed journals.
What is the CA-62 Biomarker?
CA-62 is a family of low-weight membrane transport N-glycoproteins that appear uniquely on the surface of poorly differentiated cells — including embryonic, stem, and cancer cells — during malignant transformation.
When epithelial cells undergo malignant transformation, they transform into pluripotent stem cells. The CA-62 glycoprotein appears on the surface of these cancer cells, enters the intracellular space, and then circulates in the bloodstream where it can be detected and quantified.
Critically, CA-62 levels are highest during the early stages of cancer, making it an exceptional tool for early detection — precisely when treatment is most effective.
Key Distinction: Unlike many cancer biomarkers that are organ-specific (e.g., PSA for prostate, CA-125 for ovarian), CA-62 is a universal epithelial cancer marker — it detects a wide range of epithelial carcinomas from a single blood test.
Pilot Study Results
A prospective pilot study of 1,005 asymptomatic participants demonstrated exceptional early cancer detection capabilities.
Cancer Types Detected
Pre-Cancerous & Inflammatory Conditions
*Pilot study of 1,005 participants. Results may vary in larger populations. CA-62 is a wellness test, not FDA-approved for diagnostic use.
Early-Stage Sensitivity: CA-62 vs. Galleri
The most important metric for a cancer screening test is its ability to detect cancer in its earliest, most treatable stages.
Demonstrated sensitivity exceeding 90% for Stage I and II epithelial cancers, including carcinoma in situ (Stage 0).
Published clinical data shows Galleri's sensitivity for Stage I–II cancers ranges from approximately 27.5% to 37.3%.
Why this matters: A cancer screening test must have high sensitivity for early-stage disease, where intervention is most likely to lead to a cure. A test that detects only 27.5% of early-stage cancers will miss the majority of cases when they are most treatable.Read The Lancet analysis
Peer-Reviewed Research
A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection
CA-62: A new biomarker for the detection of early-stage renal cell carcinoma
Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection
Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection
Experience the Science for Yourself
Order your CA-62 test today and benefit from the most sensitive early-stage cancer screening available.
Order Your Test — $300